

RESOLUTIONS PASSED AT THE ANNUAL GENERAL MEETING HELD ON 26 SEPTEMBER 2023

Capitalised terms used herein, unless otherwise defined, shall have the definitions ascribed to them in the annual report of the Company for the financial year ended 31 May 2023 (“AR2023”) and the appendix to the AR2023 which were despatched to shareholders of HC Surgical Specialists Limited (the “Company”) on 11 September 2023.

The Board of Directors of the Company is pleased to announce that, pursuant to Rule 704(15) of the Singapore Exchange Securities Trading Limited (“SGX-ST”) Listing Manual Section B: Rules of Catalist (the “Catalist Rules”), all of the resolutions set out in the Notice of the Annual General Meeting (“AGM”) dated 11 September 2023 were duly passed by way of poll, at the AGM held on 26 September 2023.

(a) The results of the poll on the resolutions put to the vote at the AGM are as follows:

Resolution number and details	Total number of shares represented by votes for and against the relevant resolution	For		Against		
		Number of shares	As a percentage of total number of votes for and against the resolution (%)	Number of shares	As a percentage of total number of votes for and against the resolution (%)	
Ordinary Business						
1	Re-election of Dr. Chia Kok Hoong as Director of the Company ⁽¹⁾	12,996,300	12,923,400	99.44	72,900	0.56
2	Re-election of Mr. Ooi Seng Soon as Director of the Company ⁽²⁾	12,996,300	12,923,400	99.44	72,900	0.56
3	Directors’ Fees of S\$122,000/- for the financial year ended 31 May 2023	12,996,300	12,918,800	99.40	77,500	0.60
4	Declaration of final dividend (tax-exempt one-tier) of S\$0.010 per ordinary share for the financial year ended 31 May 2023	12,996,300	12,963,900	99.75	32,400	0.25

Resolution number and details	Total number of shares represented by votes for and against the relevant resolution	For		Against		
		Number of shares	As a percentage of total number of votes for and against the resolution (%)	Number of shares	As a percentage of total number of votes for and against the resolution (%)	
Ordinary Business						
5	Re-appointment of Messrs BDO LLP as auditors of the Company	12,996,300	12,923,400	99.44	72,900	0.56
Special Business						
6	Authority to issue ordinary shares	12,996,300	12,918,800	99.40	77,500	0.60
7	Authority to issue shares under the HCSS Performance Share Plan	12,996,300	12,917,800	99.40	78,500	0.60
8	Authority to issue shares under the HCSS Employee Share Option Scheme	12,996,300	12,917,800	99.40	78,500	0.60
9	Proposed Renewal of the Share Buy-Back Mandate	12,996,300	12,959,300	99.72	37,000	0.28

Notes:

(1) Dr. Chia Kok Hoong, who was re-elected as a Director under Resolution 1, remains as the Executive Director and Medical Director of the Company.

(2) Mr. Ooi Seng Soon, who was re-elected as a Director under Resolution 2, remains as the Independent Non-executive Director, Chairman of the Audit Committee and member of the Nominating Committee and Remuneration Committee of the Company. The Board of Directors of the Company considers Mr. Ooi Seng Soon to be independent for the purpose of Rule 704(7) of the Catalist Rules.

(b) Details of the party who had abstained from voting on Resolution 9 and his shareholdings is as follows:

<u>Name</u>	<u>Number of shares held</u>
1. Dr. Heah Sieu Min	63,988,980

(c) Name of firm appointed as Scrutineer:

Entrust Advisory Pte. Ltd. was appointed as the scrutineer for the AGM.

By Order of the Board

Dr. Heah Sieu Min
Executive Director and Chief Executive Officer

Date: 26 September 2023

About HC Surgical Specialists Limited

HC Surgical Specialists Limited (the "Company") was incorporated on 1 September 2015 in Singapore and listed on the Catalist of the Singapore Exchange Securities Trading Limited on 3 November 2016. The Company, its subsidiaries and associated company are a medical services group primarily engaged in the provision of endoscopic procedures, including gastroscopies and colonoscopies, and general surgery services with a focus on colorectal procedures across a network of 15 clinics located throughout Singapore.

This announcement has been prepared by the Company and reviewed by the Company's sponsor, Novus Corporate Finance Pte. Ltd. (the "Sponsor"), in compliance with Rule 226(2)(b) of the Singapore Exchange Securities Trading Limited (the "SGX-ST") Listing Manual Section B: Rules of Catalist.

This announcement has not been examined or approved by the SGX-ST and the SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement.

The contact person for the Sponsor is Mr. Pong Chen Yih, Chief Operating Officer, at 7 Temasek Boulevard, #18-03B Suntec Tower 1, Singapore 038987, telephone (65) 6950 2188.